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a b s t r a c t
Although childhood T-cell acute lymphoblastic leukemia (T-ALL) is a high-risk disease the outcome can
vary considerably. The varying outcomes suggest that unrecognized factors may contribute to disease
progression. We report on a 2-year-old T-ALL patient presenting with a very short history of constipation
and extreme hyperleukocytosis (WBC 882109/L). In her leukemic cells we detected the very rare
translocation t(7;19)(q35;p13) and LYL1 overexpression. Additionally, we detected submicroscopic
deletions at 4q25, 7q33 and 10q23 by oligo-aCGH analysis. We suggest that LYL1 overexpression
contributed to the leukemic state and propose that the observed microdeletions may have inﬂuenced to
the rapid disease progression.
& 2013 The Authors. Published by Elsevier Ltd.
1. Introduction
T-ALL is a heterogeneous disease, accounting for 10–15% of
childhood ALLs, reviewed in [1]. The disease is less common in
young children, and presents with a median WBC count of
75109/L. Cytogenetic abnormalities are seen in approximately
50% of T-ALL patients. Cryptic translocations and deletions, invol-
ving e.g. TLX3 and TAL1, can be detected by FISH. Translocations
involving the T-cell receptor loci are found in approximately 35% of
T-ALL. Aberrant expression of one or more transcription factors,
such as for example TAL1, TAL2, LYL1, OLIG2, MYC and LMO1/2, is a
critical component of the molecular pathogenesis of T-ALL.
Activating NOTCH1 mutations are present in the majority of
T-ALL cases.
In contrast to pre-B-ALL the genomic characterization of T-ALLs has
limited prognostic impact. Thus, further improvement in treatment
choice and outcome may rely on improved characterization of
the cytogenetic and molecular events involved in this high-risk
malignancy.
We characterized the genomic complement in a pediatric T-ALL
case with a rapid and aggressive clinical course albeit discrete pre-
diagnostic symptoms. We detected the very rare t(7;19)(q35;p13),
additional submicroscopic deletions at 4q25, 7q33 and 10q23, and
a marked overexpression of LYL1.
2. Materials and methods
G-banding, FISH analyses and high resolution aCGH analysis
using CytoChip Cancer 180K microarrays (BlueGnome, Cambridge,
UK) were done on bone marrow cells at diagnosis as described [2].
The following FISH probes were used: 24XCyte (MetaSystems,
Altlussheim, Germany), whole chromosome painting probe chro-
mosome 19 (Kreatech Diagnostics, Amsterdam, Netherlands), TRB,
STIL-TAL1, TCF3, MYC (Dako, Glostrup, Denmark), MLL (Abbott
Laboratories, Illinois, USA), BlueFish probes RP11-148D11
(19p13.13) and RP11-356L15 (19p13.13) (BlueGnome) and BAC
probes RP11-840M18 (4q25), RP11-765A17 (7q33), and RP11-
79A15 (10q23.2q23.31) (EmpireGenomics, New York, USA),
centromeric probes for chromosomes 4 (D4Z1), 7 (D7Z1), and 10
(D10Z1) (Kreatech Diagnostics). Reference genome was hg18.
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Relative LYL1 gene expression was investigated with TaqMan
technology as described [3].
3. Clinical description
A previously healthy 2-year-old girl presented with a 2-week
history of constipation and sniveling. The day before admission
she developed fever to 38.4 1C. On admission she was relatively
well despite thrombocytopenia (platelets¼44109/L) and anemia
(Hgb¼4.4 mM). WBC count was 882109/L, increasing to 938109/
L within 12 h. At admission petechiae were noted without signs of
bleeding. She became unconscious 12 h later and needed ventilator.
CT scan showed a large intracerebral bleeding. Despite optimal
supportive care and a favorable response to corticosteroids with
WBC of 121109/L on day 3, new intracranial bleedings occurred.
The patient incarcerated and died on day 4 from admission.
4. Results
The leukemic cells showed 46,XX,t(7;19)(q35;p13)[23]/46,XX
[2] (Fig. 1A and B). FISH analyses of common T-ALL associated
aberrations (STIL-TAL1, MLL, TCF3 and MYC) were negative. FISH
with a commercial split-apart probe for the TRB gene at 7q35
showed 94% positivity (Fig. 1C). The only previously known
translocation partner for TRB at chromosome 19 band p13 is
LYL1. Since no commercial FISH kit for LYL1 locus is available, we
designed a split probe assay using two BAC probes (RP11-148D11
and RP11-356L15), located approximately 0.02 Mb from the LYL1
locus on each side and established that the second breakpoint was
located close to the LYL1 locus between the two probes (Fig. 1D).
The expression of LYL1 in her leukemic cells was markedly
increased compared to controls (Fig. 2). Three additional submi-
croscopic genomic changes were detected by high-resolution
oligo-aCGH analysis at 4q25 (pos. 109,182,833–109,307,857),
7q33 (pos. 136,358,795–136,622,676), and at 10q23.1q23.31 (pos.
87,745,813–90,181,623) (Fig. 3). For conﬁrmation we used the BAC
probes RP11-840M18 (4q25), RP11-765A17 (7q33), and RP11-
79A15 (10q23.2q23.31) with positions as indicated in Fig. 3.
Hybridizations with these probes conﬁrmed all deletions (Fig. 4).
In addition, we found that approximately 90% of the nuclei
contained each of the deletions, which indicates that there were
no subclones. Interestingly, we could show that the observed
deletion at 7q33 is on the same homolog as the translocation
(Fig. 4B). In silico analysis indicates that the genomic distance
between these two chromosomal aberrations is approximately
5.9 Mb. It is a possibility that the translocation t(7;19)(q35;p13)
and the del(7)(q33q33) occurred in the same genetic event, but
from these experiments it can, however, not be established that
this is the fact.
5. Discussion
Hyperleukocytosis is arbitrary deﬁned as WBC count greater than
100109/L. The critical WBC count seems different in different
leukemias. In patients with AML a leukocyte count of 50109/L
can cause severe symptoms, while patients with CLL can remain
asymptomatic even with WBC counts greater than 500109/L.
Hyperleukocytosis is associated with a high risk of severe complica-
tions and mortality [4]. Leukostasis with intracranial bleeding is
especially frequent in AML with M4 or M5 morphology but may also
Fig. 1. Cytogenetic analyses: (A) partial G-banded karyogram showing chromosome pairs 7 and 19; asterisk indicates translocated chromosomes; (B) 24-color mFISH
karyogram; asterisk indicates translocated chromosomes; (C) metaphase FISH with a commercial TRB split apart probe (7q35) and (D) metaphase FISH with a LYL1 split apart
probe, RP11-148D11 (green) and RP11-356L15 (red) at 19.13.13. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of
this article.)
Fig. 2. Relative expression of LYL1 in our present case, six T-ALL patients without
t(7;19) and four normal donors.
C. Veigaard et al. / Leukemia Research Reports 3 (2014) 4–7 5
Fig. 3. High-resolution oligo-based aCGH analysis: (A) whole genome proﬁle, arrows indicate positions of deletion; and (B) zoom view of deleted region at 4q25 (left panel),
7q33 (middle panel), and 10q23.1q23.31 (right panel). The green and red bars indicate the sizes and approximate positions of the BAC probes used for conﬁrmation (see
Fig. 4). Insets are RefSeq genes from indicated regions according to UCSC, hg18. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the
web version of this article.)
Fig. 4. FISH analyses conﬁrm the deletions detected by aCGH analysis. Aberrant chromosomes are indicated by asterisks or by text: (A) partial karyogram showing
chromosome pair 4 after metaphase FISH with centromeric probe D4Z1 and RP11-840M18. This BAC probe is the available best ﬁtting probe for conﬁrmation in this region,
and it is noted that it gives a weak signal on the aberrant chromosome 4 and a very strong signal on the normal chromosome 4. This observation is in agreement with the
size and position of the probe relative to the size and position of the deleted region on chromosome 4 as detected by aCGH analysis. (B) Partial karyogram showing
chromosome pairs 7 and 19 after 24-color karyotyping (left panel); metaphase FISH with RP11-765A17 and whole chromosome painting probe for chromosome 19 (middle
panel); and metaphase FISH with RP11-765A17 and centromeric probe D7Z1 (right panel). (C) Partial karyogram showing chromosome pair 10 after metaphase FISH with
RP11-79A15 and centromeric probe D10Z1.
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occur in ALL with extreme leukocytosis like in our patient. Hyper-
leukocytosis has signiﬁcant prognostic implications. The prognostic
impact of a high WBC count in B-ALL is greater than in T-ALL. An
association of hyperleukocytosis with speciﬁc subtypes of the leuke-
mia has been observed [5]. It was hypothesized that hyperleukocy-
tosis might be an expression of a molecular change, and that the
molecular aberration itself is responsible for the poor prognosis
rather than the actual WBC count.
The t(7;19)(q35;p13) is very rare and has only been described
in two other T-ALL cases (Table 1). Both cases had hyperleukocy-
tosis, although not to the same extent as in our patient. In the
second of reported cases the t(7;19) was cryptic, and presented
with an additional subclone containing trisomy 8. It was the sole
cytogenetic abnormality in the ﬁrst published case as well as in
ours. Only one patient is still alive. In both cases where the
patients died the disease course was rapid. LYL1 was overex-
pressed in the second case as well as in our case. The LYL1
expression was not examined in the ﬁrst case.
LYL1 belongs to the basic helix-loop-helix (bHLH) transcription
factor family, which plays important roles in a variety of develop-
mental processes, including hematopoiesis [6]. The biological
function of LYL1 is largely unknown, but its expression is restricted
to hematopoietic cells, including myelocytes, erythrocytes and
B-lymphocytes in adults. Ectopic expression of LYL1 has been
observed in a fraction of human T-ALL and an oncogenic effect of
LYL1 was demonstrated in LYL1 transgenic mice. The expression of
LYL1 can be deregulated by at least two mechanisms, either
because of a translocation or because of a microdeletion [7]. While
LYL1 overexpression has been linked to suboptimal treatment
responses [7] it is unknown how or if this is associated with
outcome.
It is becoming more evident that chromosomal abnormalities
must act in concert with other genetic lesions to induce overt
leukemia. In one of the reported t(7;19) cases an additional
submicroscopic deletion near LMO2 was found, which coincided
with elevated expression of this gene [8]. In our case we detected
three additional submicroscopic deletions by aCGH analysis.
Although several genes reside within these regions it is of
particular interest that the deletions embrace LEF1 and PTEN at
4q25 and 10q23, respectively. Deletions and inactivating muta-
tions in the LEF1 gene have been reported in pediatric T-ALL [9].
Loss of PTEN has been proposed to modulate the aggressiveness of
T-ALL and been associated with poor treatment response [10].
Although more cases are needed to disclose the underlying
biological mechanisms responsible for the extreme hyperleukocytosis
observed in our T-ALL pediatric case with t(7;19)(q35;p13) and
additional submicroscopic deletions at 4q25, 7q33 and 10q23, we
cannot rule out that deletions of PTEN or LEF1 genes or other genes in
the deleted regions may have inﬂuenced to the aggressive course in
concert with the elevated LYL1 expression.
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Table 1
Summary of published T-ALL cases with t(7;19)(q35;p13) and present case.
Reference Smith et al. [11] Homminga et al. [8] Present case
Age (yr) 19 7 2
Gender Male Male Female
WBC (109 L1) 231 119a 882
Platelets (109 L1) 373 No information 44
Immunophenotype CD1 , CD3þ , CD4þ , CD8þ , CD34 CD1 , CD2þ , CD3 , CD4þ , CD5 , CD7þ , CD8þ CD2þ , CD3 , CD4þ , CD5þ , CD7þ , CD8þ
Cytogeneticsb 46,XY,t(7;19)(q35;p13) 47,XY,þ8[6]/46,XX[7], Cryptic t(7;19)(q35;p13) revealed,
by FISH
46,XX,t(7;19)(q35;p13)[23]/46,XX[2]
LYL1 expression n.d. Overexpression Overexpression
Outcome Died, 6 mo after diagnosis Alive, 36 moþ after diagnosisa Died, 4 days after diagnosis
a Personal communication by J.P. Meijerink.
b The breakpoints of the t(7;19) has been assigned according to current band designation of involved genes.
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